Assertio Holdings, Inc. (ASRT)
- Previous Close
0.8653 - Open
0.8850 - Bid 0.8939 x 800
- Ask 0.9306 x 200
- Day's Range
0.8606 - 0.9400 - 52 Week Range
0.7500 - 8.0100 - Volume
1,098,435 - Avg. Volume
918,306 - Market Cap (intraday)
86.514M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-4.6700 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
www.assertiotx.com53
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ASRT
Performance Overview: ASRT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASRT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASRT
Valuation Measures
Market Cap
86.51M
Enterprise Value
52.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.42
Price/Book (mrq)
0.63
Enterprise Value/Revenue
0.35
Enterprise Value/EBITDA
-0.24
Financial Highlights
Profitability and Income Statement
Profit Margin
-218.28%
Return on Assets (ttm)
4.45%
Return on Equity (ttm)
-182.52%
Revenue (ttm)
152.07M
Net Income Avi to Common (ttm)
-331.94M
Diluted EPS (ttm)
-4.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
73.44M
Total Debt/Equity (mrq)
29.65%
Levered Free Cash Flow (ttm)
18.04M